These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 12390548)

  • 1. An immuno-logic hypothesis.
    Kohler H; Muller S
    J Med Primatol; 2002 Aug; 31(4-5):311-2. PubMed ID: 12390548
    [No Abstract]   [Full Text] [Related]  

  • 2. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
    Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
    J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for AIDS virus infections: cautious optimism for cell-based vaccine.
    Bhardwaj N; Walker BD
    Nat Med; 2003 Jan; 9(1):13-4. PubMed ID: 12514710
    [No Abstract]   [Full Text] [Related]  

  • 4. Alternative HIV vaccine strategies.
    Lehner T; Shearer GM
    Science; 2002 Aug; 297(5585):1276-7. PubMed ID: 12194176
    [No Abstract]   [Full Text] [Related]  

  • 5. Immune correlates of protection from HIV and AIDS - more answers but yet more questions.
    Heeney JL; Beverley P; McMichael A; Shearer G; Strominger J; Wahren B; Weber J; Gotch F
    Immunol Today; 1999 Jun; 20(6):247-51. PubMed ID: 10354547
    [No Abstract]   [Full Text] [Related]  

  • 6. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.
    Letvin NL; Huang Y; Chakrabarti BK; Xu L; Seaman MS; Beaudry K; Korioth-Schmitz B; Yu F; Rohne D; Martin KL; Miura A; Kong WP; Yang ZY; Gelman RS; Golubeva OG; Montefiori DC; Mascola JR; Nabel GJ
    J Virol; 2004 Jul; 78(14):7490-7. PubMed ID: 15220422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric adenovirus type 5/35 vector encoding SIV gag and HIV env genes affords protective immunity against the simian/human immunodeficiency virus in monkeys.
    Someya K; Xin KQ; Ami Y; Izumi Y; Mizuguchi H; Ohta S; Yamamoto N; Honda M; Okuda K
    Virology; 2007 Oct; 367(2):390-7. PubMed ID: 17628628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High hopes for HIV vaccine.
    Ahmad K
    Lancet Infect Dis; 2003 Feb; 3(2):62. PubMed ID: 12560178
    [No Abstract]   [Full Text] [Related]  

  • 9. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.
    Miyake A; Akagi T; Enose Y; Ueno M; Kawamura M; Horiuchi R; Hiraishi K; Adachi M; Serizawa T; Narayan O; Akashi M; Baba M; Hayami M
    J Med Virol; 2004 Jul; 73(3):368-77. PubMed ID: 15170630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection.
    Xu R; Srivastava IK; Kuller L; Zarkikh I; Kraft Z; Fagrouch Z; Letvin NL; Heeney JL; Barnett SW; Stamatatos L
    Virology; 2006 Jun; 349(2):276-89. PubMed ID: 16527321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic dendritic-cell vaccine for simian AIDS.
    Lu W; Wu X; Lu Y; Guo W; Andrieu JM
    Nat Med; 2003 Jan; 9(1):27-32. PubMed ID: 12496959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV and SIV CTL escape: implications for vaccine design.
    Goulder PJ; Watkins DI
    Nat Rev Immunol; 2004 Aug; 4(8):630-40. PubMed ID: 15286729
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficient priming of simian/human immunodeficiency virus (SHIV)-specific T-cell responses with DNA encoding hybrid SHIV/hepatitis B surface antigen particles.
    Puaux AL; Marsac D; Prost S; Singh MK; Earl P; Moss B; Le Grand R; Riviere Y; Michel ML
    Vaccine; 2004 Sep; 22(27-28):3535-45. PubMed ID: 15315833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3.
    Kent SJ; Dale CJ; Ranasinghe C; Stratov I; De Rose R; Chea S; Montefiori DC; Thomson S; Ramshaw IA; Coupar BE; Boyle DB; Law M; Wilson KM; Ramsay AJ
    Vaccine; 2005 Oct; 23(42):5009-21. PubMed ID: 15985317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of the SIV model in AIDS vaccine research.
    Friedrich TC; Watkins DI
    IAVI Rep; 2005; 9(2):1, 6-8. PubMed ID: 16156073
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunity in natural SIV infections.
    Silvestri G
    J Intern Med; 2009 Jan; 265(1):97-109. PubMed ID: 19093963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel simian immunodeficiency virus CTL epitopes restricted by MHC class I molecule Mamu-B*01 are highly conserved for long term in DNA/MVA-vaccinated, SHIV-challenged rhesus macaques.
    Su J; Luscher MA; Xiong Y; Rustam T; Amara RR; Rakasz E; Robinson HL; MacDonald KS
    Int Immunol; 2005 May; 17(5):637-48. PubMed ID: 15824066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of simian immunodeficiency virus-specific immune responses induced by a defective proviral DNA vaccine in macaques.
    Takeda A; Nakamura H; Matano T
    Jpn J Infect Dis; 2003 Aug; 56(4):172-3. PubMed ID: 14583643
    [No Abstract]   [Full Text] [Related]  

  • 19. CTL ontogeny and viral escape: implications for HIV-1 vaccine design.
    Yang OO
    Trends Immunol; 2004 Mar; 25(3):138-42. PubMed ID: 15036041
    [No Abstract]   [Full Text] [Related]  

  • 20. Live-attenuated HIV vaccines: how safe is safe enough?
    Murphey-Corb M
    Nat Med; 1997 Jan; 3(1):17-8. PubMed ID: 8986728
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.